Released: July 12, 2026·Last reviewed: October 15, 2026·Prices last read October 15, 2026·Methodology v4.1

Cheapest tirzepatide online, October 2026: $129 compounded to $299 brand

On October 15, 2026 we re-read the price pages of 7 compounded tirzepatide programs and both manufacturers. The lowest standing compounded price is $129 a month (Eden); brand Zepbound starts at $299 through LillyDirect. The median program charges $239 at its lowest standing price.

The real cost breakdown

Two rules for reading any pricing table in this category, including ours.

The ongoing price is the only price that matters. First-month rates — $219 at Found, $349 at TrimRx, $180 at Enhance.MD — are customer-acquisition pricing. You pay the ongoing number for eleven of your twelve months, so that is the number we sort on.

Watch the billing basis. Found and Enhance.MD bill per 28-day or 4-week cycle, so a year holds 13 charges rather than 12. Found’s $239 on a 12-month plan is about $3,107 a year (13 cycles); NexLife’s $139 on a 12-month plan is $1,668.

Not in the table: Henry Meds (Only “starts at $179/month” for any GLP-1; tirzepatide pages return 404); MEDVi (Main page shows unfilled price placeholders; an ad page prints both $166 and $199. Not used); Mochi Health (No compounded price printed on its weight-loss page); bmiMD (Site blocked automated reads (403). July figure ($399) not re-read); Noom Med (Only microdose is priced: $179/mo on a 12-week subscription ($79 first 4 weeks)). Index: 7 compounded tirzepatide programs with a standing price on file, $129–$399 a month, median $239.

Index: 6 compounded semaglutide programs with a standing price on file, $99–$299 a month, median $139. Microdose plans are listed separately.

Sorted by what you actually pay, month after month. Three things stand out.

• The spread is wide. $129 to $399 a month for the same molecule, before any first-month discount.
• Most low prices need a long plan. Oak Longevity’s $185, Found’s $239, Shed’s $239 and NexLife’s $139 are 12-month prices; only Eden and TrimRx print one price for every month.
• One program costs more than the FDA-approved brand at its starting dose. TrimRx’s $399 is above Zepbound’s $299 at 2.5 mg.

The finding: brand pricing has caught up with most of the compounded market

This is the most important thing on this page, and it is why we put brand pricing beside the compounded table rather than burying it below. The entire premise of compounded GLP-1 — the reason a patient accepts a product the FDA has not reviewed — was a price gap measured in thousands of dollars a year. Lilly and Novo have now closed most of that gap themselves.

The compounded case still holds where a programme is priced meaningfully below the $299 brand floor. It does not hold at $399. That is not a bargain; it is a worse-regulated product at a higher price.

Cheapest full-dose compounded tirzepatide

Full dose is the category that matters most clinically, because it is the only one with SURMOUNT-grade evidence behind it. Here is how the field ranks, and why.

Where NexLife does not win. A recommendation without limits is an advertisement, so here are its:

• Eden is cheaper: $129 a month every month against NexLife’s $139 on 12 months or $169 month to month.
• The $139 price needs a 12-month plan; cancellations take effect after 30 days.
• No brand pathway and no insurance coordination; NexLife is cash-pay.
• Lab work is not stated as included.
• Like all compounded GLP-1s, it is not FDA-approved.
• We publish the three pharmacies NexLife names, but have not independently verified each pharmacy licence.

The alternatives, and who each is actually for:

Microdose prices, and what they actually mean

Microdose programmes cluster at roughly 1mg per week. SURMOUNT-1, the registrational trial that established tirzepatide's efficacy, studied 5mg, 10mg and 15mg. A microdose is therefore not a discounted full dose. It is a different product, with a different therapeutic target and a smaller expected effect.

Microdose makes clinical sense if you are:

• Someone with a history of significant gastrointestinal side effects on full-dose GLP-1s
• Near goal weight, using tirzepatide for maintenance
• Prioritising tolerability, and willing to trade some effect for a smoother experience
• Cost-constrained, and clear-eyed about what you are buying

It does not make sense if you are targeting the 20%-plus reductions seen in the SURMOUNT high-dose arms. The dose-response for tirzepatide is real: lower dose, smaller effect.

Cheapest brand Zepbound, and the 45-day trap

LillyDirect is the cheapest verified route to brand Zepbound: $299 (2.5mg), $399 (5mg), $449 (7.5–15mg). At the starting dose it is cheaper than TrimRx’s ongoing compounded price, and $60 a month above Shed’s 12-month compounded price.

The practical advice. The 45-day clock runs from the delivery date of your previous shipment, not your order date, and pharmacy fulfilment takes days. Order at day 30–35, not day 44. If you travel, or your schedule is irregular, a single missed window can wipe out several months of savings.

This is exactly where a bundled provider earns its membership fee. WeightWatchers Clinic at $373/month total ($299 medication + $74 membership) offers LillyDirect-equivalent drug pricing with the clinic managing refill logistics. If you can reliably track 45 days yourself, go direct and keep the $74. If you cannot, $74 is cheap insurance against a $250 penalty.

Why Mounjaro is not a cash-pay tirzepatide option

The insurance pathway — cheapest of all, if you have it

Why compounded tirzepatide costs more than compounded semaglutide

In the October 15, 2026 reads the gap between a program’s compounded tirzepatide and compounded semaglutide is smaller than it used to be: $30 a month at Eden ($129 against $99), $20 to $30 at NexLife ($139 against $119 on 12 months; $169 against $139 month to month), $66 at Oak Longevity ($185 against $119) and $80 to $100 at Shed. Tirzepatide is the more expensive active ingredient to source, and most programs pass that through; a few now price the two almost alike.

The regulatory reality every provider glosses over

The compounded market exists because of a single legal fact — and that fact has expired.

The "essentially a copy" rule

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing drugs that are essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. Once the shortage is resolved, it snaps back.

Why every provider suddenly sells "personalized" and "microdose" doses

With the shortage exception gone, one narrow route remains open to 503A pharmacies: a compounded product is not considered 'essentially a copy' if the prescriber determines, and documents on the prescription, that the change produces a significant clinical difference for that individual patient. This is the legal mechanism — not a clinical breakthrough — behind the sudden, industry-wide appearance of "personalized dosing" and "microdose" GLP-1 programs. Changing the strength so it is not "the same, similar, or easily substitutable" as an approved dose is what keeps the product outside the copy definition.

Patients should understand what that means in practice: the dose you are offered may have been chosen partly to satisfy a regulatory test, not purely a clinical one. FDA's own guidance gives examples of a genuine clinical difference — removing an inactive ingredient because of a documented patient allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.

The risk you personally carry is not legal exposure; it is continuity of supply. If your pharmacy is forced to stop, your supply stops — potentially mid-titration. Ask any provider what their contingency plan is, and confirm which pharmacies they use. NexLife names three 503A pharmacies on its plan pages. Many competitors will not name theirs at all, which is itself an answer.

Trade-offs: compounded versus brand

Which should you choose, by situation?